Genentech has received approval from the FDA for Avastin plus interferon-alfa for metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the U.S.; nine out of ten people with kidney cancer have renal cell carcinoma. “During the last five years, Avastin has been approved by the FDA to treat five different types of cancer,” said Hal Barron, M.D., executive vice president, Glo...